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We read with great interest the letter by Dominguez-Rodriguez,
Abreu-Gonzalez and Reiter regarding our article [1]. We thank the au-
thors for pointing out that although the circadian “clock” genes are
expressed by most tissues, the suprachiasmatic nuclei of the hypothala-
mus are predominantly responsible for their secretion and regulation in
mammals and they also inﬂuence the expression of melatonin. Melato-
nin has numerous beneﬁts as described in their letter but it is secreted in
a circadian pattern. This may partly explain our ﬁndings of a circadian
variation of myocardial infarction size, depending on the time of onset
of symptoms. We admire their enthusiasm to champion melatonin as
a promising cardioprotective agent against ischemia–reperfusion injury
in the setting of ST-segment elevation myocardial infarction (STEMI)
[2]. Although the MARIA trial [2] was neutral for infarct size reduction,
a post-hoc analysis found that those presentingwithin 2.5 h of symptom
onset showed a signiﬁcant reduction in myocardial infarct size [3]. This
highlights the fact that careful patient selection is crucial for optimizing
the translation of promising cardioprotective therapies in the clinical
setting [4]. Furthermore, around 50% of STEMI patients treated by pri-
mary percutaneous coronary intervention develop microvascular
obstruction [5] and therefore any cardioprotective therapy, even if ad-
ministered via the intra-coronary route,would fail to reach themicrocir-
culation in half of these patients [6]. An alternative approach, which has
not yet been studied so far, may be to combine low dose thrombolysis
(to regain ﬂow in the microcirculation as currently being investigated
in the T-TIME trial — NCT02257294) with a promising cardioprotective
therapy (to reach the ischemic myocytes and protect against lethal
myocardial injury), in order tominimize reperfusion injury and improve
outcomes in these patients [6].
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